Aydin S, Aydin OC, Yazar MF, Aydemir H, Kantarci M, Barun S. Assessment of the potential interactions between favipiravir and radiocontrast agents. World J Radiol 2024; 16(5): 128-135 [PMID: 38845605 DOI: 10.4329/wjr.v16.i5.128]
Corresponding Author of This Article
Sonay Aydin, MD, Associate Professor, Department of Radiology, Erzincan Binali Yıldırım University, Faculty of Medicine, No. 32 Akın Street, Erzincan 24100, Türkiye. sonaydin89@hotmail.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Sonay Aydin, Huseyin Aydemir, Mecit Kantarci, Department of Radiology, Erzincan Binali Yıldırım University, Faculty of Medicine, Erzincan 24100, Türkiye
Ozlem Celik Aydin, Sureyya Barun, Department of Pharmacology, Gazi University, Faculty of Medicine, Erzincan 24100, Türkiye
Mesut Furkan Yazar, Department of Radiology, Bilecik Education and Reseach Hospital, Bilecik 11230, Türkiye
Mecit Kantarci, Department of Radiology, Atatürk University, Faculty of Medicine, Erzurum 25030, Türkiye
Author contributions: Aydin S and Yazar MF designed and performed the research and wrote the paper; Aydin CO, Kantarci M, and Aydemir H designed the research and supervised the report; Yazar MF, and Barun S designed the research and contributed to the analysis; Aydemir H, and Barun S provided clinical advice; Kantarci M supervised the report; all authors have read and approve the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Erzincan Binali Yıldırım University, Faculty of Medicine.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors declared no conflict of interest existing in this paper.
Data sharing statement: The data used to support the findings of this study are available from the corresponding author upon request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sonay Aydin, MD, Associate Professor, Department of Radiology, Erzincan Binali Yıldırım University, Faculty of Medicine, No. 32 Akın Street, Erzincan 24100, Türkiye. sonaydin89@hotmail.com
Received: February 6, 2024 Revised: April 23, 2024 Accepted: May 8, 2024 Published online: May 28, 2024 Processing time: 107 Days and 10.5 Hours
Abstract
BACKGROUND
In cases of coronavirus disease 2019 (COVID-19), favipiravir is commonly included to the therapy regimen. Drug interactions between favipiravir and other COVID-19 therapy drugs are frequently researched. However, no research on possible drug interactions between Favipiravir and radiocontrast agents, which have become almost crucial in diagnostic processes while not being part of the treatment, has been found.
AIM
To determine potential medication interactions between Favipiravir and radiocontrast agents.
METHODS
The study comprised patients who were taking Favipiravir for COVID-19 therapy and underwent a contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) test while taking the medicine. The computerized patient files of the cases included in the study, as well as the pharmacovigilance forms in the designated hospital, were evaluated for this purpose.
RESULTS
The study included the evaluation of data from 1046 patients. The study sample's mean age was 47.23 ± 9.48 years. The mean age of cases with drug interactions was statistically significant greater than that of cases with no drug interactions (P = 0.003). When evaluated with logistic regression analysis, a 1-year raises in age increases the risk of developing drug interactions by 1.63 times (P = 0.023). There was no statistically significant difference in the occurrence of medication interactions between the sexes (P = 0.090). Possible medication interactions were discovered in 42 cases (4%).
CONCLUSION
The findings of this study revealed that the most notable findings as a result of the combined use of contrast agents and favipiravir were increased creatinine and transaminase values, as well as an increase in the frequency of nausea and vomiting. The majority of drug interactions discovered were modest enough that they were not reflected in the clinic. Drug interactions become more common as people get older.
Core Tip: In cases of coronavirus disease 2019, favipiravir is commonly included to the therapy regimen. The aim of this study is to identify potential medication interactions between Favipiravir and radiocontrast agents. Possible medication interactions were discovered in 42 cases (4%). The mean age of cases with drug interactions was statistically substantially greater than that of cases with no drug interactions. There was no statistically significant difference in the occurrence of medication interactions between genders. The majority of drug interactions discovered were modest enough that they were not reflected in the clinic.
